biologics · biosimilars · specialty medicines

From first cell
to final vial.

Orvane develops, files and manufactures biosimilars and specialty medicines for partners in 62 markets. Four European sites, one quality system.

01 / 04 · development

Reference characterisation, cell line and process, analytical similarity.

scroll to turn the louvres · point to look ahead

Film: Mikhail Nilov, Pexels

( 01 ) who we are

We make complex medicines affordable, and we make them here, in Europe.

Biosimilars bring the same molecule to more patients once a patent expires. Building one takes eight years, a few hundred million euros and a quality system that never sleeps. That is the whole of our business: we do it for partners who sell in their own markets, under their own names.

  • 2009founded in Ghent
  • 4sites in four countries
  • 9inspections, zero critical findings
A row of clear glass vials on a white bench in soft light.

Photo: Jess Loiterton, Pexels

Rows of small glass sample tubes in a blue tray.

Photo: RDNE Stock project, Pexels

“A biosimilar is a promise kept for ten years, batch after batch.”

mathis verhaegen · chief executive

Film: Usman AbdulrasheedGambo, Pexels

( 02 ) orvane in numbers, 2026

  • 8,000litres

    of single-use bioreactor capacity in Ghent

  • 62markets

    supplied through 14 commercial partners

  • 11programmes

    from preclinical to marketed

  • 1,750people

    scientists, engineers and operators

( 03 ) what we do

Three businesses, one plant logic.

  1. a

    Biosimilars

    Monoclonal antibodies and fusion proteins, developed from clone to dossier and supplied under our partners' names.

  2. b

    Specialty medicines

    Ready-to-use injectables and long-acting depots that remove a step on the ward.

  3. c

    Partner manufacturing

    Our spare drug-substance and fill-finish capacity, offered to other developers by the batch or by the year.

Four syringes filled with blue liquid laid side by side on a pale blue surface.

Photo: Tara Winstead, Pexels

Film: Usman AbdulrasheedGambo, Pexels

drug substance hall · ghent
A gloved hand places a glass vial beside a row of vials.

Photo: Thirdman, Pexels

( 04 ) four pillars

What a partner gets.

( 05 ) how it works

One programme, four stages, one team.

( 06 ) pipeline

Eleven programmes, in the open.

Full pipeline

( 07 ) partners

Our medicines reach patients under fourteen partners' names.

( 08 ) leadership

The people who sign the release.

( 09 ) insights

Latest from Orvane.

    Film: Bhavesh Mariyappa, Pexels

    ( 10 ) careers

    Gown up. Sign off. Go home proud.

    Operators, analysts, engineers and writers in Ghent, Leiden, Brno and Braga. Every new starter spends their first week on a filling line, whatever their job.

    • 38open roles
    • 31%of managers promoted from the floor
    Open roles

    Film: Thilak S, Pexels

    ( 11 ) partnering

    Bring us a molecule.
    Or a market.

    License a marketed product for your territory, co-develop a programme still open for partnering, or book drug-substance and fill-finish capacity by the batch.

    ( 12 ) contact

    Write to the right desk.